For Immediate Release
For more information, contact:
Angela Kilbert, Associate Director of Education and Meetings
akilbert@sitcancer.org ~ (414) 271-2456 ~ www.sitcancer.org
ISBTC MINI-SYMPOSIUM ADDRESSES CRITICAL COMPONENT FOR FUTURE COMBINATION THERAPIES OF CANCER
Milwaukee---The International Society for Biological Therapy of Cancer (sitc) presents the 2007 "Richard V. Smalley, MD, Memorial Award" to Ernest C. Borden, MD of the Cleveland Clinic Foundation, Taussig Cancer Center in recognition of his outstanding research, work and achievements in cancer therapy.
Dr. Borden has received critical acclaim for being amongst the first to initiate clinical trials of interferons, the first human protein effective in stimulating immune mechanisms to fight cancer. In addition to developing improved approaches to clinical assessment of interferons and its inducers, Dr. Borden's laboratory has focused on the function and action of genes stimulated by interferons and anti-tumor effects of other biological therapeutics, including monoclonal antibodies. Dr. Borden also has an international reputation for his research and treatment in melanomas and sarcomas and has been listed in "Best Doctors of America" for the past 10 years.
"Dr. Borden was a pioneer in the research on interferons and immunotherapy," says Dr. Michael Atkins, sitc Past President and Executive Council Member. "His work laid the foundation for the eventual use of interferons in the adjuvant therapy of melanoma and in other cancers. Over the past decade he has continued basic science research into interferons and cytokines that are expanding our understanding of mechanisms of action and potential of these agents in the treatment of malignancy. His accomplishments and enduring commitment to biologic therapy and the sitc make him a fitting recipient of the Smalley Award."
sitc first unveiled the now annual "Richard V. Smalley, MD, Memorial Award" in 2005 in memory of Dr. Smalley's many lifetime accomplishments. The Smalley Award serves as recognition of excellence in the field of therapeutic research with biological agents and will be accompanied by an honorarium of $5,000. In association with the Smalley Award, Dr. Borden presents the scientific lecture "Interferons (IFNs) for Cancer: Defining Biological Response Modification and Full Therapeutic Potential" on Friday, November 2 from 8:00 am - 8:45 am in the Cityview Ballroom of the Seaport World Trade Center in Boston, Massachusetts.
As one of sitc's charter members in 1984, Dr. Richard V. Smalley was an integral part of the sitc fabric from the Society's inception. Dr. Smalley served on the original Board of Directors from 1984 - 90, and held office as the Society's third President from 1988 - 90, leading the Society through some of its most formative years. From 1994 - 98, the environment for biological therapy began to change and the Society faced many challenges. During this time Dr. Smalley again showed inspirational commitment by administering the Society from his own home and nurturing its continued growth. sitc's success is due, in large part, to the consummate dedication and leadership of Dr. Richard Smalley.
Founded in 1984, the International Society for Biological Therapy of Cancer (sitc) is an organization of clinicians, researchers, students, post-doctoral fellows, and allied health professionals dedicated to improving cancer patient outcomes by advancing the development and application of biological therapy through interaction, innovation and leadership.
###
